Surveillance, Epidemiology, and End Results (SEER) Program
Description
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute began collecting data on cancer incidence and survival in the United States on January 1, 1973. The SEER Program collects and publishes cancer incidence and survival data from 14 population-based cancer registries and three supplemental registries covering approximately 26 percent of the U.S. population. The database encompasses more than 3 million in situ and invasive cancer cases and approximately 170,000 new cases are added each year. Data collected includes patient demographics, year of diagnosis, geographic areas, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program also includes stage of cancer at the time of diagnosis and survival rates within each stage. The mortality data reported by SEER are provided by the National Center for Health Statistics.
The SEER Program provides cancer incidence, mortality, and survival data in an annual cancer statistics review, in monographs on relevant topics, through the Web site, and in a public-use data file. Data are available upon acceptance of a signed SEER Public-Use Data Agreement.
Selected References
Etiology
Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr.
Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.
J Natl Cancer Inst 2004 Jan 7;96(1):70-4.
Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L.
Tamoxifen therapy for breast cancer and endometrial cancer risk.
J Natl Cancer Inst 1999 Oct 6;91(19):1654-62.
Newcomb PA, Solomon C, White E.
Tamoxifen and risk of large bowel cancer in women with breast cancer.
Breast Cancer Res Treat 1999 Feb;53(3):271-7.
Cook LS, Weiss NS, Potts MS.
Second cancers after adjuvant tamoxifen therapy for breast cancer.
J Natl Cancer Inst 1997 May 7;89(9):657-9.
Mhlemann K, Cook LS, Weiss NS.
The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977.
Breast Cancer Res Treat 1994;30(2):201-4.
Drug Utilization
Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J.
Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
J Natl Cancer Inst 2002 Nov 6;94(21):1626-34.
Population Cancer Burden
Holford TR, Cronin KA, Mariotto AB, Feuer EJ.
Changing patterns in breast cancer incidence trends.
J Natl Cancer Inst Monogr 2006;(36):19-25.
Davies L, Welch HG.
Epidemiology of head and neck cancer in the United States.
Otolaryngol Head Neck Surg 2006 Sep;135(3):451-7.
Fairley TL, Cardinez CJ, Martin J, Alley L, Friedman C, Edwards B, Jamison P.
Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001.
Cancer 2006 Sep 1;107(5 Suppl):1153-61.
Cost/Cost Effectiveness
Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD.
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
Am J Med 2005 Aug;118(8):850-7.
Treatment/Cancer Survivorship
Morris AM, Wei Y, Birkmeyer NJ, Birkmeyer JD.
Racial disparities in late survival after rectal cancer surgery.
J Am Coll Surg 2006 Dec;203(6):787-94.
Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CM Jr, Freeman JL.
Pancreatic cancer in the general population: Improvements in survival over the last decade.
J Gastrointest Surg 2006 Nov;10(9):1212-23; discussion 1223-4.
Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC.
Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis.
Cancer 2006 Nov 15;107(10):2392-400.
|
